Sung Soo Ahn1, Taejun Yoon2, Yong-Beom Park3,4, Maria Prendecki5, Gurjeet Bhangal5, Stephen P McAdoo6, Sang-Won Lee7,8. 1. Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea. 2. Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Republic of Korea. 3. Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea. 4. Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. 5. Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, Du Cane Road, London, W120NN, UK. 6. Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, Du Cane Road, London, W120NN, UK. s.mcadoo@imperial.ac.uk. 7. Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea. sangwonlee@yuhs.ac. 8. Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. sangwonlee@yuhs.ac.
Abstract
BACKGROUND: To investigate whether serum chitinase-3-like 1 protein (YKL-40) is associated with disease activity in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). METHODS: ELISA was performed in serum samples from AAV patients who were enrolled in our prospective observational cohort to estimate levels of YKL-40. Birmingham vasculitis activity score (BVAS) (version 3), five factor score (FFS), and short form-36 (SF-36), as well as clinical and laboratory data were collected. Kidney expression of YKL-40 was assessed by immunohistochemical staining using renal biopsy tissues from ANCA-associated glomerulonephritis patients (AAGN). Severe AAV and FFS were defined as BVAS ≥ 12 and FFS ≥ 2, and the correlations between laboratory variables, BVAS, FFS, and SF-36 score were assessed using linear regression analysis. The optimal cut-off of serum YKL-40 for severe AAV and high FFS was calculated using the receiver operator characteristic curve analysis. RESULTS: Of the included 60 patients, 32 (53.3%), 17 (28.3%), and 11 (18.3%) were classified as microscopic polyangiitis, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis. The median BVAS and FFS were 7.0 and 1.0, whereas the mean SF-36 physical and mental component scores were 50.5 and 58.3. Serum YKL-40 level was higher in patients with severe AAV and high FFS compared to those without (p = 0.007 and p < 0.001); multivariable linear regression analysis revealed that serum YKL-40 was independently associated with BVAS, FFS, and SF-36 scores. On kidney tissues obtained from AAGN patients, strong cytoplasmic staining of YKL-40 was found in cells present in inflammatory lesions. In addition, AAV patients had higher levels of serum YKL-40 compared to those with systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, and healthy control. The proportion of patients having severe AAV and high FFS was significantly higher in those with serum YKL-40 > 221.3 ng/mL and > 227.1 ng/mL than those without (relative risk 2.852 and 7.000). In 12 patients with serial YKL-40 testing, 11 patients (91.7%) exhibited a reduction in serum YKL-40 levels following a decrease in disease activity (p < 0.001). CONCLUSION: Our findings suggest that serum YKL-40 may be a clinically useful biomarker to assess AAV disease activity. TRIAL REGISTRATION: Retrospectively registered.
BACKGROUND: To investigate whether serum chitinase-3-like 1 protein (YKL-40) is associated with disease activity in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). METHODS: ELISA was performed in serum samples from AAV patients who were enrolled in our prospective observational cohort to estimate levels of YKL-40. Birmingham vasculitis activity score (BVAS) (version 3), five factor score (FFS), and short form-36 (SF-36), as well as clinical and laboratory data were collected. Kidney expression of YKL-40 was assessed by immunohistochemical staining using renal biopsy tissues from ANCA-associated glomerulonephritis patients (AAGN). Severe AAV and FFS were defined as BVAS ≥ 12 and FFS ≥ 2, and the correlations between laboratory variables, BVAS, FFS, and SF-36 score were assessed using linear regression analysis. The optimal cut-off of serum YKL-40 for severe AAV and high FFS was calculated using the receiver operator characteristic curve analysis. RESULTS: Of the included 60 patients, 32 (53.3%), 17 (28.3%), and 11 (18.3%) were classified as microscopic polyangiitis, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis. The median BVAS and FFS were 7.0 and 1.0, whereas the mean SF-36 physical and mental component scores were 50.5 and 58.3. Serum YKL-40 level was higher in patients with severe AAV and high FFS compared to those without (p = 0.007 and p < 0.001); multivariable linear regression analysis revealed that serum YKL-40 was independently associated with BVAS, FFS, and SF-36 scores. On kidney tissues obtained from AAGN patients, strong cytoplasmic staining of YKL-40 was found in cells present in inflammatory lesions. In addition, AAV patients had higher levels of serum YKL-40 compared to those with systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, and healthy control. The proportion of patients having severe AAV and high FFS was significantly higher in those with serum YKL-40 > 221.3 ng/mL and > 227.1 ng/mL than those without (relative risk 2.852 and 7.000). In 12 patients with serial YKL-40 testing, 11 patients (91.7%) exhibited a reduction in serum YKL-40 levels following a decrease in disease activity (p < 0.001). CONCLUSION: Our findings suggest that serum YKL-40 may be a clinically useful biomarker to assess AAV disease activity. TRIAL REGISTRATION: Retrospectively registered.
Authors: P A Merkel; D D Cuthbertson; B Hellmich; G S Hoffman; D R W Jayne; C G M Kallenberg; J P Krischer; R Luqmani; A D Mahr; E L Matteson; U Specks; J H Stone Journal: Ann Rheum Dis Date: 2008-07-29 Impact factor: 19.103
Authors: P Scott Eastman; William C Manning; Ferhan Qureshi; Douglas Haney; Guy Cavet; Claire Alexander; Lyndal K Hesterberg Journal: J Pharm Biomed Anal Date: 2012-06-12 Impact factor: 3.935
Authors: Julia S Johansen; Benny Vittrup Jensen; Anne Roslind; Dorte Nielsen; Paul A Price Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-02 Impact factor: 4.254
Authors: Timothy S C Hinks; Tom Brown; Laurie C K Lau; Hitasha Rupani; Clair Barber; Scott Elliott; Jon A Ward; Junya Ono; Shoichiro Ohta; Kenji Izuhara; Ratko Djukanović; Ramesh J Kurukulaaratchy; Anoop Chauhan; Peter H Howarth Journal: J Allergy Clin Immunol Date: 2016-02-03 Impact factor: 10.793
Authors: Yannick van Sleen; Maria Sandovici; Wayel H Abdulahad; Johan Bijzet; Kornelis S M van der Geest; Annemieke M H Boots; Elisabeth Brouwer Journal: Rheumatology (Oxford) Date: 2019-02-25 Impact factor: 7.580